Navigation Links
1.2 Million Dollars Recently Awarded to Institute for Myeloma and Bone Cancer Research
Date:1/26/2009

FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA

LOS ANGELES, Jan. 26 /PRNewswire-USNewswire/ -- IMBCR's "Cure Myeloma Project" is the nation's foremost effort to find a cure for multiple myeloma, a blood cancer that resides in bone marrow. Led by premier scientists in the world of myeloma research, James R. Berenson, M.D., Haiming Chen, M.D., Ph.D. and Zhi-Wei Li, Ph.D., this multi-phase research project's overall goal is to specifically target myeloma cells while leaving surrounding healthy cells untouched.

Over the past five years, researchers and scientists at IMBCR have been responsible for creating many of the novel therapeutics currently used to extend the quality of life and lifespan of myeloma patients throughout the world.

About Multiple Myeloma and Blood Cancers: The American Cancer Society predicts that over 80,000 people are currently living with myeloma in the US and over 20,000 new cases are diagnosed each year. Approximately 10,000 people die each year from multiple myeloma. The Leukemia & Lymphoma Society estimates that 894,543 people in the US are presently battling blood cancers that include leukemia, lymphoma and myeloma. Blood cancers are the second most fatal form of cancer, second only to lung cancer.

About IMBCR: Headquartered in Los Angeles, California, IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma and other forms of blood cancer. IMBCR research findings have been presented at numerous scientific meetings throughout the world and its research has been published in most major oncology journals. www.imbcr.org

About FJC and Myeloma Research Fund:

FJC is a premier group of donor advised funds and public charity that provides total management of charitable giving. To date, over $100,000,000 has been given in grants to charities in the United States and around the world. FJC contributed $1,000,000 to IMBCR in support of the "Cure Myeloma Project". www.FJC.org

The Myeloma Research Fund (MRF) is a donor-advised fund of the Silicon Valley Community Foundation. The MRF has risen over $3 million to date, all of which has gone toward funding multiple myeloma research. MRF contributed an additional $200,000 to the "Cure Myeloma Project". Please visit www.myelomaresearchfund.org.


'/>"/>
SOURCE Institute for Myeloma and Bone Cancer Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quest Diagnostics Board Authorizes $500 Million in Share Repurchases
2. CHPA, Nielsen: OTC Heartburn Therapy Saves Nearly $800 Million Annually, Vast Majority of OTC Heartburn Consumers Satisfied
3. FRC Condemns President Obamas $441 Million Bailout of International Abortions
4. 60 Million Worldwide Carry Heart Disease Mutation
5. United Way of Central Maryland Aims to Raise $1 Million for Emergency Food, Shelter and Utility Assistance
6. UTSA receives $1.2 million gift from Kleberg Foundation
7. President Obama Gives the Unborn at Least a 24 Hour Reprieve, Postpones $441 Million Bailout of International Abortions, Says Family Research Council
8. Kuwait Purchases 5.4 Million Doses of Emergency Nuclear Radiation Drug from Nukepills.com
9. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
10. MSU researcher receives $1.5 million grant for childhood obesity intervention study
11. Global Health Community Commits Over $630 Million in Aggressive Push for Polio Eradication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... ... Immunotherapy has emerged as one of the most promising options for the ... next revolution in our fight against this complex disease. One of the most effective ... such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry tests ...
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the official ... Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony on ... of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than 1,400 ...
(Date:3/28/2017)... YORK (PRWEB) , ... March 28, 2017 , ... ... NTX Technology™, is the first technology to directly address the resolution to globally ... NTX Technology™ is a patented compound of FDA and TTB approved ingredients that ...
(Date:3/28/2017)... ... , ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts ... Secret. Dr. Wentz talked about journey and research recently on a blog and discussed ... the only solution to deal with thyroid disease. , Dr. Wentz completed her ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader ... Emergency Response Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the ... their kind, the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... 29, 2017 Neurim Pharmaceuticals ("Neurim") ... obtain exclusive marketing rights for Neurim,s new Rx PedPRM in ... ... treat sleep disorders in children with Autism Spectrum Disorders (ASD) and ... approved for children. The collaboration with Exeltis will help ...
(Date:3/29/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The global patient safety and risk management software market ... Patient safety has become a priority for almost ... significantly in the last decade and is currently on the verge ...
Breaking Medicine Technology: